Skip to main content

Advertisement

SpringerLink
Log in

Cyclophosphamide treatment in active multiple sclerosis

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Objective

Cyclophosphamide (CYC) is an alkylating agent with immunosuppressive effect by inhibiting DNA synthesis and producing apoptosis used in many autoimmune diseases, including multiple sclerosis (MS). Here, we analyze the efficacy of CYC treatment in relapsing-remitting (RRMS) and active secondary progressive MS (SPMS) in our center with a monthly scheme.

Methods

Patients with MS treated with CYC and a follow up of at least 36 months were eligible for inclusion. All participants had received a standard CYC regimen. The EDSS score mean annualized relapse rate (ARR) and progression index (PI) were measured as efficacy outcomes at 12, 24, and 36 months. Outcomes were also analyzed comparing disease course and activity.

Results

A total of 16 patients were included (50% male, 18.75% RRMS and 81.25% SPMS). EDSS remained stable along the follow-up period, with 62.5% improving or maintaining the same EDSS score at 12 months. PI decreased 14% and 21% at 12 and 24–36 months of follow-up, respectively. ARR decreased 20% after 12 months, 19% after 24 months, and 30.23% after 36 months. Median differences in ARR were higher in patients with high relapse activity (0.60 vs 0.07, p = 0.001) and malignant course (0.60 vs 0.17, p = 0.027). PI also differed with higher mean differences in patients with high relapse activity (0.70 vs 0.03, p = 0.016) and malignant course (1.17 vs 0.03, p = 0.003).

Conclusions

CYC continues to be a valid therapeutic option, especially in regions with limited access to high-efficiency therapies particularly in patients with high relapsing activity and malignant course.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Compston A, Coles A (2008) Multiple sclerosis. Lancet. 372:1502–1517. https://doi.org/10.1016/S0140-6736(08)61620-7

    Article  CAS  PubMed  Google Scholar 

  2. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018) Multiple sclerosis. Lancet. 391:1622–1636. https://doi.org/10.1016/S0140-6736(18)30481-1

    Article  PubMed  Google Scholar 

  3. Hartung DM (2017) Economics and cost-effectiveness of multiple sclerosis therapies in the USA. Neurotherapeutics. 14:1018–1026. https://doi.org/10.1007/s13311-017-0566-3

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ahlmann M, Hempel G (2016) The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 78:661–671. https://doi.org/10.1007/s00280-016-3152-1

    Article  CAS  PubMed  Google Scholar 

  5. Awad A, Stue O (2009) Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord. https://doi.org/10.1177/1756285609344375

  6. Weiner HL, Cohen JA (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 8:142–154. https://doi.org/10.1191/1352458502ms790oa

    Article  CAS  PubMed  Google Scholar 

  7. Perini P, Calabrese M, Rinaldi L, Gallo P (2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 6:183–190. https://doi.org/10.1517/14740338.6.2.183

    Article  CAS  PubMed  Google Scholar 

  8. La Mantia L, Milanese C, Mascoli N, D’Amico R, Weinstock-Guttman B (2002) Cyclophosphamide for multiple sclerosis. In: Cochrane database of systematic review. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.cd002819

  9. Hommes OR, Prick JJG, Lamers KJB (1975) Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 78:59–72. https://doi.org/10.1016/S0303-8467(75)80007-2

    Article  CAS  PubMed  Google Scholar 

  10. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL (1983) Intensive immunosuppression in progressive multiple sclerosis. N Engl J Med 308:173–180. https://doi.org/10.1056/nejm198301273080401

    Article  CAS  PubMed  Google Scholar 

  11. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, Lapierre Y, Herndon R, Lehrich JR, Hauser SL, Turel A, Fisher M, Birnbaum G, Mcarthur J, Butler R, Moore M, Sigsbee B, Safran A (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the northeast cooperative multiple sclerosis treatment group. Neurology. 43:910–918. https://doi.org/10.1212/wnl.43.5.910

    Article  CAS  PubMed  Google Scholar 

  12. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R (1994) The impact of blinding on the results of a randomized, placebo–controlled multiple sclerosis clinical trial. Neurology. 44:16–20. https://doi.org/10.1212/wnl.44.1.16

    Article  CAS  PubMed  Google Scholar 

  13. Likosky WH, Fireman B, Elmore R, Eno G, Gale K, Goode GB, Ikeda K, Laster J, Mosher C, Rozance J, Richmon J, Rosenberg S, Samman A, Sternbach R, Whaley J, Fehrenbacher L (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54:1055–1060. https://doi.org/10.1136/jnnp.54.12.1055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Weinstock-Guttman B, Kinkel RP, Cohen JA, Ransohoff RM, Schwetz K, Gogol D et al (1997) Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 3:178–185

    Article  Google Scholar 

  15. Hohol MJ, Olek MJ, Orav EJ, Stazzone L, Hafler DA, Khoury SJ, Dawson DM, Weiner HL (1999) Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler J 5:403–409. https://doi.org/10.1177/135245859900500i606

    Article  CAS  Google Scholar 

  16. Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF (1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99:142–149. https://doi.org/10.1016/S0165-5728(99)00039-9

    Article  CAS  PubMed  Google Scholar 

  17. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. https://doi.org/10.1002/ana.22366

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83:278–286. https://doi.org/10.1212/WNL.0000000000000560

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1444–1452. https://doi.org/10.1212/wnl.33.11.1444

    Article  CAS  PubMed  Google Scholar 

  20. Poser S, Raun NE, Poser W (1982) Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol Scand 66:355–362. https://doi.org/10.1111/j.1600-0404.1982.tb06856.x

    Article  CAS  PubMed  Google Scholar 

  21. Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand’Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M (2016) Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann. Neurol 80:89–100. https://doi.org/10.1002/ana.24682

    Article  PubMed  Google Scholar 

  22. Kieseier BC, Jeffery DR (2010) Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord 3:277–291. https://doi.org/10.1177/1756285610379885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Perini P, Gallo P (2003) Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J Neurol 250:834–838. https://doi.org/10.1007/s00415-003-1089-x

    Article  CAS  PubMed  Google Scholar 

  24. Khan OA, Zvartau-Hind M, Caon C, Din MU, Cochran M, Lisak D, Tselis AC, Kamholz JA, Garbern JY, Lisak RP (2001) Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 7:185–188. https://doi.org/10.1177/135245850100700309

    Article  CAS  PubMed  Google Scholar 

  25. Filippini G, Del Giovane C, Vacchi L, D’Amico R, Di Pietrantonj C, Beecher D, Salanti G (2013) Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013. https://doi.org/10.1002/14651858.CD008933.pub2

  26. Blank N, Lisenko K, Pavel P, Bruckner T, Ho AD, Wuchter P (2016) Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease. Eur J Haematol 97:78–82. https://doi.org/10.1111/ejh.12686

    Article  CAS  PubMed  Google Scholar 

  27. Gladstone DE, Golightly MG, Brannagan TH (2007) High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients. J Neuroimmunol 190:121–126. https://doi.org/10.1016/j.jneuroim.2007.07.005

    Article  CAS  PubMed  Google Scholar 

  28. La Mantia L, Eoli M, Salmaggi A, Torri V, Milanese C (1998) Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Ital J Neurol Sci 19:32–36. https://doi.org/10.1007/BF03028809

    Article  PubMed  Google Scholar 

  29. Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, Locher E, Coyle PK (2006) High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 63:1388–1393. https://doi.org/10.1001/archneur.63.10.noc60076

    Article  PubMed  Google Scholar 

  30. Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, Richert ND, Pardo CA, Yousem DM, Hammond E, Quigg M, Trecker C, McArthur JC, Nath A, Greenberg BM, Calabresi PA, Kerr DA (2008) Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 65. https://doi.org/10.1001/archneurol.65.8.noc80042

  31. Schwartzman RJ, Simpkins N, Alexander GM, Reichenberger E, Ward K, Lindenberg N, Topolsky D, Crilley P (2009) High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther 15:118–127. https://doi.org/10.1111/j.1755-5949.2008.00072.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Patti F, Lo Fermo S (2011) Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis 1. https://doi.org/10.4061/2011/961702

  33. Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, Wiertlevski S, Defer G, Gout O, Berthier F, Danzon A (2008) Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 14:399–405. https://doi.org/10.1177/1352458507083625

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Neurology and Neurosurgery, Manuel Velasco Suarez, Insurgentes Sur 3877, Tlalpan, 14269, Mexico City, Mexico

    Enrique Gómez-Figueroa, Efrain Gutierrez-Lanz, Alonso Alvarado-Bolaños, Adriana Casallas-Vanegas, Christian Garcia-Estrada, Indhira Zabala-Angeles, Rivas-Alonso Veronica & José Flores-Rivera

  2. The American British Cowdray Medical Center, Mexico City, Mexico

    Enrique Gómez-Figueroa, Arturo Cadena-Fernandez & José Flores-Rivera

  3. National Institute of Medical Sciences and Nutrition, Mexico City, Mexico

    Treviño-Frenk Irene

Authors
  1. Enrique Gómez-Figueroa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Efrain Gutierrez-Lanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alonso Alvarado-Bolaños
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adriana Casallas-Vanegas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Garcia-Estrada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Indhira Zabala-Angeles
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Arturo Cadena-Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rivas-Alonso Veronica
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Treviño-Frenk Irene
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. José Flores-Rivera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Enrique Gómez-Figueroa or José Flores-Rivera.

Ethics declarations

Ethical approval

Ethical approval was obtained from the ethics committee of National Institute of Neurology.

Informed consent

Informed consent was obtained from the patients.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gómez-Figueroa, E., Gutierrez-Lanz, E., Alvarado-Bolaños, A. et al. Cyclophosphamide treatment in active multiple sclerosis. Neurol Sci 42, 3775–3780 (2021). https://doi.org/10.1007/s10072-021-05052-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-021-05052-1

Keywords

Search

Navigation